Clinical Trial Update: Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study evaluating the safety of chronic administration of basiliximab (Simulect) in first kidney transplant recipients has been terminated. The spons…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Simulect (Basiliximab)

Snippet

Sponsor: Drexel University College of Medicine | Conditions: End Stage Renal Disease | Phase 2, Phase 3 | Status: TERMINATED